"Losartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
| Descriptor ID |
D019808
|
| MeSH Number(s) |
D02.455.426.559.389.185.475 D03.383.129.308.507 D03.383.129.617.467
|
| Concept/Terms |
Losartan- Losartan
- 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
Losartan Potassium- Losartan Potassium
- Potassium, Losartan
- Losartan Monopotassium Salt
- Monopotassium Salt, Losartan
- Salt, Losartan Monopotassium
|
Below are MeSH descriptors whose meaning is more general than "Losartan".
Below are MeSH descriptors whose meaning is more specific than "Losartan".
This graph shows the total number of publications written about "Losartan" by people in this website by year, and whether "Losartan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 1 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Losartan" by people in Profiles.
-
Losartan May Not Prevent Vestibular Schwannoma Growth or Related Hearing Loss During Observation. Otol Neurotol. 2024 Jul 01; 45(6):690-695.
-
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A. 2023 05 09; 120(19):e2300706120.
-
Dysregulated myosin in Hermansky-Pudlak syndrome lung fibroblasts is associated with increased cell motility. Respir Res. 2022 Jun 23; 23(1):167.
-
Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology. 2022 08; 76(2):429-444.
-
A pilot clinical trial with losartan in Myhre syndrome. Am J Med Genet A. 2021 03; 185(3):702-709.
-
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. J Pediatr. 2020 07; 222:213-220.e5.
-
Biologically Regulated Marrow Stimulation by Blocking TGF-?1 With Losartan Oral Administration Results in Hyaline-like Cartilage Repair: A Rabbit Osteochondral Defect Model. Am J Sports Med. 2020 03; 48(4):974-984.
-
Skin fibroblasts of patients with geleophysic dysplasia due to FBN1 mutations have lysosomal inclusions and losartan improves their microfibril deposition defect. Mol Genet Genomic Med. 2019 09; 7(9):e844.
-
Losartan, an Angiotensin II Type 1 Receptor Antagonist, Alleviates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain by Inhibiting Inflammatory Cytokines in the Dorsal Root Ganglia. Mol Neurobiol. 2019 Nov; 56(11):7408-7419.
-
Cathepsin B-Mediated NLRP3 Inflammasome Formation and Activation in Angiotensin II -Induced Hypertensive Mice: Role of Macrophage Digestion Dysfunction. Cell Physiol Biochem. 2018; 50(4):1585-1600.